BioLineRx Ltd. (BLRX)

Market Cap	52.97M
Revenue (ttm)	4.80M
Net Income (ttm)	-60.61M
Shares Out	82.77M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	301,089
Open	0.655
Previous Close	0.642
Day's Range	0.611 - 0.680
52-Week Range	0.550 - 2.530
Beta	0.92
Analysts	Strong Buy
Price Target	12.50 (+1,853.13%)
Earnings Date	May 28, 2024

About BLRX

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of ski...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2011
• Employees: 79
• Stock Exchange: NASDAQ
• Ticker Symbol: BLRX

Analyst Forecast

According to 2 analysts, the average rating for BLRX stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 1,853.13% from the latest price.

Price Target

$12.5

(1,853.13% upside)

Analyst Consensus: Strong Buy